Earendil Labs partners with Genentech for AI-designed bispecific antibodies in oncology. $1.5B+ deal includes $55M upfront payment and milestone targets.

FDA approves Elevar's Lyrfigtu (lirafugratinib) for previously treated cholangiocarcinoma with FGFR2 fusion. Learn about this breakthrough cancer treatment.

Astellas doses first patient in Phase III setidegrasib trial for KRAS G12D lung cancer. First-in-class treatment with no approved competitors. Read more.

Arcturus Therapeutics unveils LUNAR 2.0 platform with 38-fold potency increase for OTC deficiency treatment. Phase II interim data released. Read more.

Eli Lilly partners with Beijing-based InnoCare Pharma in $3.25B strategic collaboration for oncology and autoimmune disease ...

Anthropic's autonomous AI agents identified a previously unknown enzyme system (ART) in bacteriophages, analyzing 1.94 billion protein clusters. Read ...

Variant Bio expands collaboration with Boehringer Ingelheim into cardiovascular disease with USD 250M in potential payments. Read the latest biotech news.

Enveda secures $311M Series E funding led by Catalio Capital to advance three clinical-stage programs powered by AI drug discovery. Learn more.

Celldex reports positive Phase 3 results for barzolvolimab in chronic urticaria, meeting primary endpoints. Read the ...

Siemens Healthineers and Novo collaborate to expand non-invasive blood-based testing for MASLD and MASH. Learn about this healthcare partnership.

Glycomine receives FDA Breakthrough Therapy Designation for GLM101, a novel treatment for PMM2-CDG. Learn about this rare disease breakthrough.

Viking's VK2735 sustains 97% weight loss with monthly injections. Discover how this GLP-1/GIP agonist offers flexible ...